Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06781034

Descriptive Study on MRI Contrast of Acute Cerebral Hemorrhage in Different Microangiopathies

Cerebral haemorrhage represents a minority of acute vascular syndromes (less frequent than ischemic stroke, at around 20%), but with a therapeutic impasse, having no specific treatment.

Arterial contrast ("spot sign") within the hematoma has been described in CT scans as a risk factor for further enlargement and poor prognosis.

An equivalent marker has also been described in gadolinium-enhanced MRI.

By studying the radiological appearance of gadolinium "spot signs" on MRI, which has better parenchymal resolution, the researchers propose to retrace the phenomenology of the acute phase of cerebral hemorrhage in order to better estimate the risk of radiological aggravation by subgroup, which could serve as a target population for future therapeutic trials.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cerebral Hemorrhage Acute Lobar Haematoma Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Hemorrhage Intracranial Hemorrhages Nervous System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU de Nîmes

Nîmes, Gard, 30029, France

Location status: Recruiting

Location contact

Anissa MEGZARI

CONTACT

[email protected]

+ 33 4.66.68.30.09

Teodora PARVU, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with acute cerebral hematomas from existing databases of cerebral amyloid angiopathy and hypertensive microangiopathy managed at Nîmes University Hospital;
  • Patients who have undergone a follow-up cerebral CT scan in the event of worsening or for follow-up.

Exclusion criteria

  • Patient refusing to participate

Treatment and study plan

None, pure observational study

Other

None, pure observational study

Primary outcomes

  1. Presence of spot sign on gadolinium MRI

    Time frame: baseline

    Presence of spot sign on gadolinium MRI (Yes/No)

  2. Morphologic description of gadolinium MRI spot sign

    Time frame: baseline

    morphological (shape, location within the hematoma) description of spot signs on brain MRI

  3. Quantitative description of gadolinium MRI spot sign

    Time frame: baseline

    Quantitative (number and categorial) description of spot signs on brain MRI

Secondary outcomes

  1. association of spot sign with hematoma expansion on follow-up CT

    Time frame: Baseline

    association of spot sign with hematoma expansion on follow-up CT(Yes/No)

  2. Association with the underlaying pathology

    Time frame: Baseline

    Association with the underlaying pathology as identified by the authors (Yes/No)

Study contacts

Contact information is provided by the study sponsor or research team.

Teodora PARVU

CONTACT

[email protected]

04.66.68.32.61

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nīmes

Other

Registry information

Acronym: GADO-ICH

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 17, 2025
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.